Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending oral doses of NNC0487-0111 in Japanese males with obesity
jRCT2071230058Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amycretin in obesity (4 arms), sponsored by Novo Nordisk. Started Sep 2023; status: completed.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2071230058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230058.